BIO-THERA SOLUTIONS, LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.68 CNY | +1.91% |
|
+4.71% | -15.91% |
| 10:29am | China Grants Clinical Trial Approval to Bio-Thera's Anti-Tumor Combination Therapy | MT |
| Apr. 29 | Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 17,077 | 14,360 | - | - |
| Enterprise Value (EV) 1 | 17,077 | 14,360 | 14,360 | 14,360 |
| P/E ratio | -42.5 x | -694 x | 25.1 x | 10.8 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 9.64 x | 5.78 x | 3.25 x |
| EV / Revenue | - | 9.64 x | 5.78 x | 3.25 x |
| EV / EBITDA | - | 67.1 x | 17.9 x | 7.86 x |
| EV / FCF | - | 67.6 x | 29.2 x | 8.72 x |
| FCF Yield | - | 1.48% | 3.43% | 11.5% |
| Price to Book | - | 10.7 x | 7.32 x | 4.18 x |
| Nbr of stocks (in thousands) | 414,080 | 414,080 | - | - |
| Reference price 2 | 41.24 | 34.68 | 34.68 | 34.68 |
| Announcement Date | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 0.7 | - | 1,490 | 2,484 | 4,415 |
| EBITDA 1 | -969.4 | - | 214 | 803.5 | 1,828 |
| EBIT 1 | -1,024 | - | 142.5 | 717 | 1,739 |
| Operating Margin | -146,269.71% | - | 9.56% | 28.87% | 39.39% |
| Earnings before Tax (EBT) 1 | -1,023 | - | -22 | 672 | 1,564 |
| Net income 1 | -1,023 | -401.3 | -22 | 571 | 1,329 |
| Net margin | -146,088.83% | - | -1.48% | 22.99% | 30.1% |
| EPS 2 | - | -0.9700 | -0.0500 | 1.380 | 3.210 |
| Free Cash Flow 1 | - | - | 212.6 | 492.4 | 1,646 |
| FCF margin | - | - | 14.27% | 19.83% | 37.28% |
| FCF Conversion (EBITDA) | - | - | 99.32% | 61.29% | 90.04% |
| FCF Conversion (Net income) | - | - | - | 86.24% | 123.85% |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 213 | 492 | 1,646 |
| ROE (net income / shareholders' equity) | - | - | 8.3% | 31.8% | 42.9% |
| ROA (Net income/ Total Assets) | - | - | 5.25% | 18.3% | 29.1% |
| Assets 1 | - | - | -419 | 3,120 | 4,567 |
| Book Value Per Share 2 | 1.780 | - | 3.240 | 4.740 | 8.300 |
| Cash Flow per Share 2 | -1.690 | - | -0.9300 | 1.460 | 2.420 |
| Capex 1 | - | - | 116 | 128 | 156 |
| Capex / Sales | - | - | 7.75% | 5.15% | 3.52% |
| Announcement Date | 2/27/20 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
34.68
CNY
Average target price
54
CNY
Spread / Average Target
+55.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.91% | 1.99B | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +2.65% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -37.64% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- 688177 Stock
- Financials Bio-Thera Solutions, Ltd.